U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07136857) titled 'Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)' on Aug. 15.
Brief Summary: This study is evaluating an investigational drug, eptacog beta (EB), for the treatment and prevention of acute bleeding episodes in people with Glanzmann Thrombasthenia, a rare inherited bleeding disorder. Eptacog beta (EB) is not currently approved by the U.S. Food and Drug Administration (FDA) for this condition.
The study will assess the effectiveness and safety of eptacog beta (EB) when used to treat serious bleeding events, and in an optional phase, when used routinely to prevent bleeding. During the first three (3) months, participants wil...